reason report
analyst day recap margin expans still intact potenti
bottom line remain outperform agil given lead
posit chemic energi end-market maintain
well-diversifi posit across healthcar growth market
pharma lst diagnost analyst day agil highlight
margin expans stori remain intact see drive
bp oper margin expans next year us
agil also remain top-lin growth stori multipl growth driver
includ ultivo mass spec intuvo gc therapeut nucleic acid
oligo busi potenti lasergen long-term pt
margin expans remain intact agil highlight margin
expans stori remain intact guid adjust oper margin
higher end today despit
technolog invest lasergen agil see number driver
includ top-lin growth integr high growth bolt-on new
product improv gross margin profil includ ultivo intuvo
order fulfil suppli chain organ deliv
 annual past year agil see come
next year increas agil ep estim modestli
larg due oper margin improv
drive valu custom pois captur market share
believ one innov product offer price
deliv valu custom ultivo intuvo fit profil
see agil continu deliv least organ growth longer
lasergen compet provid innov
valu price product workflow lasergen expect drive
growth longer term agil expect system compet
aggress op sequenc recal agil
exercis option acquir lasergen total agil
believ lasergen address instrument solut gap
enabl integr clinic workflow solut cancer
genet disord product launch
china continu deliv despit recent food safeti
hiccup believ china food safeti concern alreadi price
china continu deliv growth agil like beyond
compani growth estim long-term believ china
food sale return back earlier agil maintain
lead posit china given legaci posit sale account
food test revenu world-wide
life scienc tool diagnost
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu us million ep exclud item amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate agil share outperform price target view agil
posit believ compani hold lead posit environment chemic
food test market around world maintain well-diversifi posit across
healthcar biopharma life scienc tool lst diagnost compani also repres
margin expans opportun medium long-term spin-off keysight
electron manag busi becom pure-play lst compani agil
focus deliv adjust oper margin believ
achiev exceed long-term leadership ceo mcmullen agil
compet aggress multipl market deliv solid growth biopharma sale
maintain either posit across end-market includ food
environment chemical/energi emerg market includ china continu post
double-digit growth agil posit capit given sizabl exposur
geographi intuvo product cycl could repres opportun
current under-appreci view agil repres compani develop
core root industri chemic electron market year transform
life scienc tool technolog leader diversifi access lead end-market
agil host annual analyst day reiter guidanc laid long-term
guidanc next year maintain core revenu growth outlook
y/i core revenu growth outlook view three highlight
analyst day event continu top-lin growth three core segment
continu margin expans improv core oper margin improv fx impact
improv via potenti upsid could aris lasergen acquisit
compani note overal address market opportun compani plan
captur market end agil goal drive
oper margin ep growth continu employ strategi goal
compani expect see adjust oper margin trend upward rang
next three year
agil plan invest next three year bring faster smaller product
lower cost ownership sale forc front agil start see benefit past effort
combin sale forc acquisit strengthen oper margin manag note
oper margin heavili affect activ draw attent
power one strategi power one strategi agil entail one central hr
depart legal depart etc power one platform compani claim
elimin financ cost move everyth exist structur
agil see number driver drive core oper margin increment
improv includ top-lin growth integr high growth bolt-on new product
improv gross margin profil includ ultivo intuvo order fulfil suppli chain
organ of deliv annual past year see
come next year
agil continu top-lin grower
agil expect trajectori continu fuel top-lin growth compani three core
segment lsag life scienc appli market group acg agil crosslab group
dgg diagnost genom group grew mid-to-upp singl digit
lsag unit deliv revenu y/i core revenu growth
account largest agil three busi unit lsag unit compani
look penetr intuvo ga separ market opportun
infinitylab liquid separ market opportun ultivo quadrupol lc/m liquid
acg unit record second highest revenu agil segment talli
revenu repres y/i core growth strateg direct acg
solut digit enabl differenti custom experi lab
pressur need complet high-qual run less fund primari workflow
solut market driver pharma specif biopharma market food environ
market china market expans experi consum benefit
e-commerce segment acg chemistri suppli consum lead
omlif scienc appli market crosslab genom inc
unit compris agil total revenu acg china market fuel
matur aftermarket massiv instal base digit connect custom
segment revenu growth expect come cancer diagnost nucleic acid drug-
develop region expans china leverag agil digit capabl
nucleic acid drug-develop busi yield revenu expect
compris revenu due facil expans
market perspect growth end-market expect fuel differ
driver pharma growth larg base biopharma agil believ biolog market
go grow annual come year due lot invest space
agil current largest instal base chemic energi market ten
thousand unit expect propel growth china penetr compani
recent rais growth rate outlook manag believ china market grow
next sever year
agil state custom analyz chemic energi market import
featur growth diagnost clinic busi expect driven cancer
diagnost agil believ know space well make invest serv
custom want multi-mod offer includ ms agil believ
academia govern market repres largest attain market share opportun
compani current revenu come user base agil plan
penetr academia govern expand portfolio offer focus
cancer research market food environment market driven regulatori
complianc polici compani note half agil food busi locat china
manag bullish china growth execut plan china fuel
enhanc expertis chang regul develop chromatography/m market
china repres highest usag
figur market opportun end-market
market opportun total opportunitylt market revenueprimari growth diagnosticsacadem indiachem base china agil inc
china market compris total address market
delv deeper geograph revenu mix china make meaning portion
agil total revenu today agil total revenu come china shine
spotlight regulatori commerci landscap countri china revenu
come lsag busi unit acg dgg agil plan expand
footprint china come year leverag larg instrument instal base
aftermarket growth agil also believ build clinic diagnost franchis help
catalyz growth market
lasergen acquisit potenti present upsid
agil exercis option acquir lasergen total march agil
invest lasergen stake recent agil announc exercis
option acquir rest lasergen stake believ creat potenti
path agil launch sequenc platform sequenc chemistri long-term agil
believ lasergen address instrument solut gap enabl integr
clinic workflow solut cancer genet disord agil work fulli
integr lasergen expect first commerci avail system hit market
lasergen go bring togeth companion diagnost patholog lab experi
lasergen go posit take share routin cancer care market dynam
area includ increas regulatori clariti improv payor coverag decentr drive
broad adopt manag indic lasergen like compet
sequenc volum high go mid-level market
manag note acquisit bolt-on acquisit rather technolog
acquisit lasergen outlier compani describ bolt-on acquisit
acquisit understand technolog agil know end-market
agil understand target busi model target could easili integr
compani expect continu activ plan pursu bolt-on acquisit
agil share current trade ev/ebitda under-valued compar
life scienc tool peer group averag
believ ev/ebitda valuat provid best measur agil valu
month price target remain expect agil trade premium
averag lst group ev/ebitda multipl result appli
ev/ebitda multipl ebitda estim given number tailwind
posit agil better compar lst peer group continu exposur robust
biopharma growth china demand believ premium warrant sustain
primari risk price target includ
biopharma declin pose greatest risk agil margin expans plan declin
biopharma fund could highli impact agil revenu given revenu lever
biopharma industri believ gener biopharma price risk mute given
elect outcom howev impact regulatori chang could see
biopharma compani becom cautiou spend could impact capit
equip purchas includ agil slowdown biopharma fund would result
downsid risk estim valuat biomolecul forecast ramp
drug market mid-teen believ prolifer drive use
agil mass spectromet character molecul pronounc
slowdown biopharma core growth requir margin expans would
slowdown global budget research could pose downsid risk forecast tighten
budget govern academ fund could result lower revenu rel
estim agil much academ government exposur
competitor nevertheless slowdown academ spend could
headwind plan margin expans assum expect core growth furthermor
restrict global budget could result shift focu strategi growth could
increas oper risk declin government spend could risk downsid
forecast growth nih spend flat low-single-digit
soft demand emerg market could derail growth forecast geopolit risk emerg
market could disrupt oper downsid risk valuat forecast geopolit
risk could also impact agil strategi creat higher barrier entri exist futur
market agil oper numer intern market includ china middl east
europ macroeconom impact chines market could lead declin compani
revenu regul chines polici could also caus restrict oper lead lower
activ china question remain china concern detail
headwind could emerg polici risk
continu volatil energi chemic sector could impact growth agil
consider exposur revenu chemic energi industri agil expect
recoveri next year continu volatil crude oil could result downsid risk
agil expect low-single-digit growth next year volatil oil price could impact
budget next year spend certain countri dictat commod price
would lead lower spend chemic energi
dollar million except per share data
good sold
sg sale
 sale
oper expens sale
compani report leerink partner estim
